Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients

BACKGROUND: First-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are commonly used in EGFR-mutation-positive advanced non-small-cell lung cancer (NSCLC) with no relevant differences in efficacy in randomised clinical trials (RCTs). Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Pluzanski, Adam, Krzakowski, Maciej, Kowalski, Dariusz, Dziadziuszko, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640619/
https://www.ncbi.nlm.nih.gov/pubmed/33148621
http://dx.doi.org/10.1136/esmoopen-2020-001011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640619/
https://www.ncbi.nlm.nih.gov/pubmed/33148621
http://dx.doi.org/10.1136/esmoopen-2020-001011

Ejemplares similares